Valuation: Stoke Therapeutics, Inc.

Market Cap 1.7B 1.53B 1.41B 1.28B 2.38B 162B 2.42B 16.88B 6.73B 84.92B 6.39B 6.26B 269B P/E 2026 *
-7.28x
P/E 2027 * -7.32x
Enterprise Value 1.5B 1.34B 1.24B 1.13B 2.1B 143B 2.13B 14.86B 5.92B 74.74B 5.63B 5.51B 237B EV / Sales 2026 *
46.8x
EV / Sales 2027 * 32.6x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.07%
1 week+2.84%
Current month+1.58%
1 month+3.57%
3 months-10.14%
6 months-20.76%
Current year-16.79%
1 week 24.52
Extreme 24.52
26.52
1 month 22.05
Extreme 22.05
27.22
Current year 22.05
Extreme 22.05
40.22
1 year 20.32
Extreme 20.32
40.22
3 years 3.4
Extreme 3.4
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 2025-03-18
Chief Tech/Sci/R&D Officer 54 2014-05-31
Director of Finance/CFO 49 2024-05-06
Director TitleAgeSince
Chairman 65 2015-06-30
Director/Board Member 67 2014-05-31
Director/Board Member 72 2015-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 Sell

General Counsel

-627 0.0011%
10/1/26 Sell

Chief Technology Officer

-1,051 0.0018%
9/23/26 Free

Director

39,674 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%+2.84%-16.50%+683.68% 1.69B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.21%-0.56%+45.07%+214.91% 38.21B
Weighted average by Cap. +3.23%-0.30%+47.02%+163.77%

Financials

2026 *2027 *
Net sales 32.02M 28.7M 26.5M 24.03M 44.79M 3.05B 45.4M 317M 126M 1.6B 120M 118M 5.05B 44.83M 40.17M 37.1M 33.63M 62.69M 4.27B 63.55M 444M 177M 2.23B 168M 165M 7.07B
Net income -241M -216M -199M -181M -336M -22.91B -341M -2.38B -950M -11.99B -903M -884M -37.95B -262M -235M -217M -197M -367M -24.97B -372M -2.6B -1.04B -13.07B -984M -963M -41.36B
Net Debt -204M -183M -169M -153M -286M -19.44B -290M -2.02B -806M -10.18B -766M -750M -32.21B -242M -217M -200M -182M -339M -23.05B -343M -2.4B -955M -12.06B -908M -889M -38.18B
Projected Income Statement - Annual - Stoke Therapeutics, Inc.
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
26-10-28 US$26.41 +1.07% 779,984
26-10-27 US$26.13 +2.63% 1,325,215
26-10-26 US$25.46 +1.68% 2,083,446
26-10-23 US$25.04 -2.57% 2,156,224
26-10-22 US$25.70 +0.08% 1,346,399
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Stoke Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.41USD
Average target price
46.46USD
Spread / Average Target
+75.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Stoke Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. STOK Stock